



Solosec[®] (secnidazole) – New indication

- On July 1, 2021, Lupin Pharmaceuticals announced the FDA approval of Solosec (secnidazole), for the treatment of trichomoniasis caused by *Trichomonas vaginalis* (*T. vaginalis*) in adults.
 - Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, treat partners of infected patients simultaneously in order to prevent reinfection.
- Solosec is also approved for the treatment of bacterial vaginosis in adult women.
- The approval of Solosec for the new indication was based on a randomized, placebo-controlled, delayed treatment, double-blind study in 147 female patients with trichomoniasis. Patients received a single dose of Solosec or placebo. The modified intent-to-treat (mITT) population included all randomized patients who were culture positive for *T. vaginalis* and negative for other sexually transmitted infections. The primary endpoint was microbiological cure at the test of cure visit (occurred 6 to 12 days after initial dosing), defined as testing negative for *T. vaginalis*.
 - In the mITT population (N = 131), microbiological cure was achieved in 92.2% of patients receiving Solosec vs. 1.5% of patients receiving placebo (treatment difference: 90.7, 95% CI: 80.7, 96.5; p < 0.001).
- Solosec was also evaluated in four open-label studies in males. Reported cure rates ranged from 91.7% (165/180) to 100% (30/30) at time points ranging from 2 to 20 days.
- The most common adverse reaction (≥ 2%) with Solosec use was vulvovaginal candidiasis.
- The recommended dose of Solosec for the treatment of bacterial vaginosis and trichomoniasis is a single 2-gram packet of granules taken once orally.
- Since trichomoniasis is a sexually transmitted disease, treat sexual partners with the same dose and at the same time.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.